Lack of Outcome Data Sharing Hinders ALS Treatment Progress

The article discusses the challenges in treating amyotrophic lateral sclerosis (ALS) due to the lack of a systematic mechanism to share outcome data across specialized ALS centers. Despite the availability of treatment data, it remains isolated within individual centers, preventing the collective learning and optimization of ALS therapies.

Details

ALS is a devastating disease that kills most patients within 2-5 years of diagnosis. While there are three FDA-approved drugs that can modestly slow the disease progression, the treatment response varies significantly across different ALS subtypes and patient demographics. The article highlights that specialized ALS centers, each treating around 30,000 American patients, are accumulating valuable outcome data on treatments, but this data is not being shared or integrated across centers. This isolation prevents the collective learning and optimization of ALS therapies. The article also explains why federated learning, a proposed solution for cross-institutional data sharing, is not viable for ALS due to the small patient cohorts at individual centers and the inherent heterogeneity of the disease. The lack of a real-time data sharing system delays the integration of insights from similar patient cases into the treatment of new patients, hindering the progress in ALS care.